Evidence map›Paper›PMID 36845709›Full record

ArticleFrontiers in oncology2023

Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories.

Glykeria Gkoliou, Andreas Agathangelidis, Georgos Karakatsoulis, Chrysavgi Lalayanni, Apostolia Papalexandri, Alejandro Medina, Elisa Genuardi, Katerina Chlichlia, Evdoxia Hatjiharissi, Maria Papaioannou and 8 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. IMGTAntibodies (Basel, Switzerland) · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Autophagy-related mechanisms for treatment of multiple myeloma.Cancer drug resistance (Alhambra, Calif.) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Glykeria GkoliouInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Andreas AgathangelidisDepartment of Biology, School of Science, National and Kapodistrian University of Athens, Athens, Greece.
Georgos KarakatsoulisInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Chrysavgi LalayanniHematology Department and HCT Unit, G. Papanikolaou Hospital, Thessaloniki, Greece.
Apostolia PapalexandriHematology Department and HCT Unit, G. Papanikolaou Hospital, Thessaloniki, Greece.
Alejandro MedinaHematology Department, University Hospital of Salamanca, Salamanca, Spain.
Elisa GenuardiDepartment of Molecular Biotechnologies and Health Sciences, Hematology Division, University of Turin, Turin, Italy.
Katerina ChlichliaDepartment of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupoli, Greece.
Evdoxia HatjiharissiFirst Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Maria PapaioannouFirst Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Evangelos TerposDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
Cristina JimenezHematology Department, University Hospital of Salamanca, Salamanca, Spain.
Ioanna SakellariHematology Department and HCT Unit, G. Papanikolaou Hospital, Thessaloniki, Greece.
Simone FerreroDepartment of Molecular Biotechnologies and Health Sciences, Hematology Division, University of Turin, Turin, Italy.
Marco LadettoDepartment of Molecular Biotechnologies and Health Sciences, Hematology Division, University of Turin, Turin, Italy.
Ramon Garcia SanzHematology Department, University Hospital of Salamanca, Salamanca, Spain.
Chrysoula BelessiHematology Department, Nikea General Hospital, Piraeus, Greece.
Kostas StamatopoulosInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The analysis of the immunogenetic background of multiple myeloma (MM) has proven key to understanding disease ontogeny. However, limited information is available regarding the immunoglobulin (IG) gene repertoire in MM cases carrying different heavy chain isotypes. Here, we studied the IG gene repertoire in a series of 523 MM patients, of whom 165 and 358 belonged to the IgA and IgG MM groups, respectively. IGHV3 subgroup genes predominated in both groups. However, at the individual gene level, significant (p<0.05) differences were identified regarding IGHV3-21 (frequent in IgG MM) and IGHV5-51 (frequent in IgA MM). Moreover, biased pairings were identified between certain IGHV genes and IGHD genes in IgA versus IgG MM. Turning to the imprints of somatic hypermutation (SHM), the bulk of rearrangements (IgA: 90.9%, IgG: 87.4%) were heavily mutated [exhibiting an IGHV germline identity (GI) <95%]. SHM topology analysis disclosed distinct patterns in IgA MM versus IgG MM cases expressing B cell receptor IG encoded by the same IGHV gene: the most pronounced examples concerned the IGHV3-23, IGHV3-30 and IGHV3-9 genes. Furthermore, differential SHM targeting was also identified between IgA MM versus IgG MM, particularly in cases utilizing certain IGHV genes, alluding to functional selection. Altogether, our detailed immunogenetic evaluation in the largest to-date series of IgA and IgG MM patients reveals certain distinct features in the IGH gene repertoires and SHM. These findings suggest distinct immune trajectories for IgA versus IgG MM, further underlining the role of external drive in the natural history of MM.

Indexed as

immunogeneticsimmunoglobulin aimmunoglobulin gimmunoglobulin gene repertoireimmunoglobulin isotypesmultiple myeloman-glycosylationsomatic hypermutation (SHM)

Identifiers

PMID36845709
PMCPMC9945080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.